CD13 promotes hepatocellular carcinogenesis and sorafenib resistance by activating HDAC5‐LSD1‐NF‐κB oncogenic signaling

Abstract Rationale CD13 is a new marker for liver cancer stem cells (CSCs) that contributes to sorafenib resistance in hepatocellular carcinoma (HCC). However, the underlying mechanism of CD13 in HCC sorafenib resistance remains enigmatic. Methods The expression of CD13 in HCC cell lines and tissues...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Bo Hu, Yang Xu, Yuan‐Cheng Li, Jun‐Feng Huang, Jian‐Wen Cheng, Wei Guo, Yue Yin, Yang Gao, Peng‐Xiang Wang, Sui‐Yi Wu, Jian Zhou, Jia Fan, Xin‐Rong Yang
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Wiley 2020-12-01
coleção:	Clinical and Translational Medicine
Assuntos:	CD13 HDAC5 hepatocellular carcinoma patient derived tumor grafts sorafenib‐resistance
Acesso em linha:	https://doi.org/10.1002/ctm2.233
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!